Subscribe to Entrepreneur for $5
Subscribe

Implied Volatility Surging for Theravance Biopharma (TBPH) Stock Options

Investors need to pay close attention to Theravance Biopharma (TBPH) stock based on the movements in the options market lately.

By
This story originally appeared on Zacks

Investors in Theravance Biopharma TBPH need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 21, 2022 $12.50 Call had some of the highest implied volatility of all equity options today.

- Zacks

What is Implied Volatility?

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?

Clearly, options traders are pricing in a big move for Theravance Biopharma shares, but what is the fundamental picture for the company? Currently, Theravance Biopharma is a Zacks Rank #3 (Hold) in the Medical - Drugs industry that ranks in the Bottom 40% of our Zacks Industry Rank. Over the last 60 days, three analysts have increased their earnings estimates for the current quarter, while two have dropped their estimates. The net effect has widened our Zacks Consensus Estimate for the current quarter from a loss of 34 cents per share to a loss of 40 cents in that period.

Given the way analysts feel about Theravance Biopharma right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.



5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Theravance Biopharma, Inc. (TBPH): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research